Kiora Pharmaceuticals Inc. (KPRX) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Kiora Pharmaceuticals Inc. (NASDAQ: KPRX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $1.56 (-11.36% 1D, market cap $7.8M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, KPRX ranks #864 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), KPRX carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, TCRT (Alaunos Therapeutics Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $7.8M) and CURX (Curanex Pharmaceuticals Inc) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $7.7M). Among the 5-stock peer group, KPRX leads on earnings multiple (N/A) while KPRX leads on capital efficiency (-35.0% ROIC).
Per KPRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001372514), Kiora Pharmaceuticals Inc. generated $0 in revenue (-100.0% YoY), -$10.8K in net income, and -$10.1M in free cash flow against $24.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 29.1 (OVERSOLD (<32))
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
While KPRX currently carries a cautious 30/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.49) and Max Pain ($1.64) forces dealer call-delta covering toward $3.06.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Kiora Pharmaceuticals Inc. (KPRX) dropped -11.36% to $1.56, trading at 2% of its 52-week range ($1.55 – $2.91). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering Kiora Pharmaceuticals Inc. (KPRX) market action, institutional positioning, and fundamental catalysts.
Moomoo report covering Kiora Pharmaceuticals Inc. (KPRX) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Kiora Pharmaceuticals Inc. (KPRX) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Kiora Pharmaceuticals Inc. (KPRX) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Kiora Pharmaceuticals Inc. (KPRX) market action, institutional positioning, and fundamental catalysts.
www.dars.gov.et report covering Kiora Pharmaceuticals Inc. (KPRX) market action, institutional positioning, and fundamental catalysts.
Traders Union report covering Kiora Pharmaceuticals Inc. (KPRX) market action, institutional positioning, and fundamental catalysts.
Traders Union report covering Kiora Pharmaceuticals Inc. (KPRX) market action, institutional positioning, and fundamental catalysts.
Gainers Glaukos (NYSE:GKOS) shares rose 30.8% to $237.26 during Thursday's regular session. The company's market cap stands at $10.7 billion. The company's, Q3 earnings came out yesterday. Teladoc Health
Kiora Pharmaceuticals In-Licenses Late-Stage, Oral Neuroprotective Calpain Inhibitor for Central Retinal Artery Occlusion (CRAO) with Planned Expansion into NAION; Asset Completed Phase 3 Clinical Trial in CRAO in
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on KPRX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for KPRX. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Kiora Pharmaceuticals Inc. (KPRX) ranks #864 by composite RQD confidence (30/100, grade E) and #915 by equity capitalization ($7.8M). Within this direct 5-issuer industry benchmark cohort, KPRX leads on earnings valuation at N/A trailing P/E, while KPRX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. TCRT currently holds the highest overall quantitative score in the immediate peer group at 36/100 (D-) compared with KPRX at 30/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| KPRX
ACTIVE
Kiora Pharmaceuticals Inc. | E | 30/100 | — | — | -35.0% | -11.36% | $7.8M | Benchmark Subject |
| TCRT Alaunos Therapeutics Inc. | D- | 36/100 | — | — | -35.0% | +3.18% | $7.8M | /tcrt-vs-kprx → |
| CURX Curanex Pharmaceuticals Inc | E | 34/100 | — | — | -35.0% | +4.45% | $7.7M | /curx-vs-kprx → |
| UPC Universe Pharmaceuticals Inc. (Class A) | E | 33/100 | — | 35.3% | — | -3.25% | $7.7M | /upc-vs-kprx → |
| MTVA MetaVia Inc. | E | 31/100 | — | — | -35.0% | -5.88% | $7.8M | /mtva-vs-kprx → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Kiora Pharmaceuticals Inc. (KPRX) reported GAAP revenue of $0 (-100.0% vs. FY2024 revenue of $16.0M ) , GAAP net income of -$10.8K, operating cash flow of -$10.0M, and free cash flow of -$10.1M (-217.8% YoY). On the balance sheet, KPRX closed FY2025 with $24.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$10.8K | -$10.0M | -$10.1M | $24.3M | — |
| FY2024 (FY) | 2024-12-31 | $16.0M | $3.6K | $8.6M | $8.6M | $36.5M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$12.5K | -$9.6M | -$9.6M | — | — |
As of 2026-11-02, Kiora Pharmaceuticals Inc. (NASDAQ: KPRX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $1.56 (-11.36% 1D, market cap $7.8M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, KPRX ranks #864 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), KPRX carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, TCRT (Alaunos Therapeutics Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $7.8M) and CURX (Curanex Pharmaceuticals Inc) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $7.7M). Among the 5-stock peer group, KPRX leads on earnings multiple (N/A) while KPRX leads on capital efficiency (-35.0% ROIC).
Per KPRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001372514), Kiora Pharmaceuticals Inc. generated $0 in revenue (-100.0% YoY), -$10.8K in net income, and -$10.1M in free cash flow against $24.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
KPRX last traded at $1.56 (-11.36% on volume of 100,696 shares), positioning the stock -37.35% below its 50-day simple moving average ($2.49) and -35.27% below its 200-day simple moving average ($2.41). Across its 52-week range of $1.55 to $2.91, KPRX sits at the 0.7% percentile with a 14-day RSI of 29.1 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.36 to $1.76).
Why KPRX Stock dropped -11.36% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, KPRX scores 30 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine at 4/20 (ROIC -35%; FCF yield 0%), Whale 13F Flow at 3/20 (institutional accumulation and options positioning), Insider Conviction at 5/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 8/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 10/20 (Altman Z 2.5; Piotroski F 1/9; Debt/Equity 0.5).
For a prospective investor, the weakest pillars are the cash engine and the smart-money signals, which together indicate that the business is not currently generating cash returns and that informed capital is not showing conviction. The balance-sheet pillar is the strongest of the five but still reflects a weak Piotroski reading. Macro fit is neutral-to-modest given a beta of 1.0. The rating points to downside-risk considerations rather than upside drivers. Any upside case would need to rest on catalysts outside the reported fundamentals, which the source data does not quantify.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-12.8M | $-0.0M | N/A | $-10.1M | $8.7M | N/A |
| FY 2024 | $16.0M | $4.5M | $0.0M | N/A | $8.6M | $3.8M | N/A |
| FY 2023 | $0.0M | $-12.6M | $-0.0M | N/A | $-9.6M | N/A | N/A |
Per the market data, gross, operating, and net margins are each 0%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 1/9, with Debt/Equity at 0.5. The FY 2024 period is the only one showing positive operating income and free cash flow, while FY 2025 returned to an operating loss of $-12.8M. The reported debt figures are N/A across all periods, so the balance-sheet leverage picture is limited to the Debt/Equity ratio cited in the RQD rating.
Real-time company headlines, analyst actions, and sector developments for Kiora Pharmaceuticals Inc. (KPRX) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Kiora Pharmaceuticals Inc. (KPRX) market action, institutional positioning, and fundamental catalysts.
Moomoo report covering Kiora Pharmaceuticals Inc. (KPRX) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Kiora Pharmaceuticals Inc. (KPRX) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Kiora Pharmaceuticals Inc. (KPRX) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Kiora Pharmaceuticals Inc. (KPRX) market action, institutional positioning, and fundamental catalysts.
www.dars.gov.et report covering Kiora Pharmaceuticals Inc. (KPRX) market action, institutional positioning, and fundamental catalysts.
Traders Union report covering Kiora Pharmaceuticals Inc. (KPRX) market action, institutional positioning, and fundamental catalysts.
Traders Union report covering Kiora Pharmaceuticals Inc. (KPRX) market action, institutional positioning, and fundamental catalysts.
Welcome to the KPRX (Kiora Pharmaceuticals Inc.) Roar Pit. Current RQD Composite is 30/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on KPRX, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Kiora Pharmaceuticals Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on KPRX, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $1.76 (52-wk range $1.55 - $2.91), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).